Bicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary

Bicycle Therapeutics

29/10/2026 19:49

Bicycle Therapeutics PLC BCYC.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -85 cents.  The mean expectation of ten analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from -65 cents to -7 cents per share.
Revenue rose 190.2% to $34.06 million from a year ago; analysts expected $6.07 million. 
Bicycle Therapeutics PLC's reported EPS for the quarter was a loss of 15 cents​.
The company reported a quarterly loss of $10.48 million.
Bicycle Therapeutics PLC shares had risen by 5.4% this quarter and lost 45.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 15.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $10.00, about 61.2% above its last closing price of $3.88
This summary was machine generated from LSEG data October 29 at 07:49 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.43
-0.15
Beat
Jun. 30 2026 
-0.58
-0.72
Missed
Mar. 31 2026 
-0.62
-0.87
Missed
Dec. 31 2025 
-0.94
-0.29
Beat